Vor Biopharma (VOR) rose ~17% on Tuesday after J.P. Morgan initiated its coverage with an Overweight recommendation and a Dec. 2026 price target of $43, citing a potential blockbuster status for the ...
In recent months, Vor Biopharma closed a US$424.83 million shelf registration, repriced employee stock options, and reported positive late-stage clinical data for its autoimmune drug candidate ...
Investing.com - JPMorgan has initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a price target of $43.00, highlighting the potential of the company’s telitacicept ...
Vor Biopharma Inc. offers a high-risk, high-reward play on U.S. commercialization of telitacicept, a dual-target autoimmune drug approved in China. Complex warrant issuances and reverse stock split ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Jason Fernando is a professional investor and writer who enjoys tackling and communicating complex business and financial problems. The market approach is a method for determining the value of an ...
Julia Kagan is a financial/consumer journalist and former senior editor, personal finance, of Investopedia. Andy Smith is a Certified Financial Planner (CFP®), licensed realtor and educator with over ...
IRAEmpire has released a new and updated list of the best crypto IRA companies in the US to help consumers make better-informed decisions. DALLAS, TEXAS / ACCESS Newswire / December 26, 2025 / More Am ...
Vor Biopharma strengthens presence in engineered cell therapy Precision platforms support expanding hematologic treatment design Clinical development enhances visibility across oncology research Vor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback